Financial Shenanigans
Financial Shenanigans
Star Health scores 32 / 100 — Watch. The accounting foundation is structurally sound: no restatement in a 10+ year history, nil promoter pledge, a reputable auditor without qualification, and a solvency buffer of 2.21× against the 1.5× regulatory minimum. What prevents a Clean rating is a combination of metric presentation complexity — three simultaneous PAT frameworks in circulation for FY2025/FY2026, and GWP growth cited at materially different rates depending on which basis is chosen — and a worsening regulatory compliance record that includes an IRDAI show cause notice (December 2024) and a data breach penalty (₹3.4 Cr, 2024). None of this is concealed; all items are disclosed somewhere. The risk is that investors anchor on the metric that makes the business look best. The one data point that would most change the grade: the formal IND AS annual report for FY2026, which must reconcile Indian GAAP to IND AS and will confirm or clarify the ₹141 Cr PAT gap between the two frameworks.
The Forensic Verdict
Forensic Risk Score (0-100)
Red Flags
Yellow Flags
FY2025 Loss Ratio (%)
Solvency (× minimum)
13-Shenanigan Scorecard
Breeding Ground
The governance structure is a net forensic positive. WestBridge Capital, a professional PE firm, controls the promoter block at 57.67% with two board nominees, providing the kind of financial-discipline oversight that family-founder structures often lack. Audit Committee Chairman Rohit Bhasin brings 40+ years of experience at a Big Four firm, AIG, and Standard Chartered — specifically the right background for an insurer. Former SEBI Member R.K. Agarwal also sits on the board, adding regulatory expertise. No promoter shares are pledged. The auditor (Walker Chandiok & Co, a Grant Thornton affiliate) shows no resignation or qualification in available filings.
Founder V. Jagannathan resigned from the board in June 2023, ending a 17-year involvement. CEO Anand Roy, who has been with the company since inception, stepped up as sole MD & CEO, limiting management discontinuity. CEO compensation is dominated by fixed pay (₹582L of ₹919L total), reducing incentive to manipulate short-term metrics for bonus purposes.
Two events introduce a breeding ground flag: the IRDAI Show Cause Notice issued December 4, 2024, for violations identified during a general inspection in January–February 2022 (under IRDAI Health Insurance Regulations 2016 and TPA Health Service Regulations 2016); and the ₹3.4 Cr IRDAI penalty for cybersecurity lapses following the August 2024 data breach, in which approximately 31 million customer records were reportedly exposed. Neither penalty is financially material, but both indicate structural weaknesses in compliance and information security controls that were not caught internally first.
Earnings Quality
The central earnings story for FY2025 is straightforward: GWP grew 10% on the statutory 1/n basis but net income fell 24%, entirely driven by a loss ratio spike from 66.4% to 70.3%. This pushed the combined ratio into underwriting-loss territory at 101.1%. By FY2026, underwriting profitability recovered (combined ratio 98.8%; loss ratio 68.7%), consistent with management's explanation that FY2025 was hurt by vector-borne disease claims seasonality and a suboptimal group health portfolio, both of which were subsequently repriced.
No earnings manipulation shenanigans are visible in the income statement. Investment income grew steadily alongside the total investment portfolio (yield stable at 7.7–7.8% on the shareholder fund), suggesting no unusual asset shuffling. Operating expense ratio improved modestly. Commission expense as a share of net earned premium rose 120 basis points year-on-year (from 13.2% to 14.4%), consistent with a growing agency channel mix rather than aggressive channel incentives.
The COVID-era losses (FY2021: −₹1,086 Cr; FY2022: −₹1,041 Cr) were genuine and industry-wide — the combined ratio hit 122% and 118% respectively. The recovery from FY2023 onward shows no big-bath behavior because the losses were not concentrated around a management change (Anand Roy was already effectively running operations before Jagannathan's formal exit in June 2023).
The one earnings quality concern is the IND AS vs Indian GAAP PAT gap for FY2025. The audited annual report shows PAT of ₹646 Cr under Indian GAAP. In the Q4 FY2026 earnings call, management referenced FY2025 as a ₹787 Cr base for YoY growth (IND AS basis). The ₹141 Cr difference — roughly 22% of reported Indian GAAP PAT — is not small. Management states the IND AS financials have been reviewed by joint auditors for multiple quarters, so this is an accounting framework difference, not manipulation. But until the formal IND AS annual report for FY2026 is published with a reconciliation note, an investor reading the annual report and the earnings call simultaneously sees inconsistent profit figures with no bridge.
GWP has compounded steadily at approximately 20% over 8 years; net income has been volatile, with two COVID loss years and the FY2025 claims spike clearly visible. The recovery trajectory is intact, but earnings quality is directly hostage to loss ratio — a metric whose management depends on actuarial reserve adequacy (see Section 5).
The FY2023 combined ratio is not in the available structured data — a disclosure gap in the recovery narrative. The trajectory from FY2024 (97.3%) to FY2025 (101.1%) to FY2026 (98.8%) is a standard cyclical swing for a health insurer hit by seasonal disease patterns; it does not indicate systematic reserve manipulation. However, the gap between the FY2024 peak-performance year and the FY2025 loss-ratio spike (3.9 percentage points) is material and worth watching under the IND AS reserve adequacy framework that IRDAI mandated from April 2026.
The three-framework chart illustrates the metric confusion. Indian GAAP (₹646 Cr, FY2025) is the statutory audited figure. IND AS Actual (₹787 Cr, FY2025) is what management cited in investor calls as the YoY base. IND AS Normalized (₹843 Cr for FY2025; ₹1,222 Cr for FY2026) is the management-constructed figure that replaces actual investment yields with a fixed 8% assumption. Each has a legitimate use, but all three coexisting without a published reconciliation table creates an investor information risk.
Cash Flow Quality
The cash flow statement for Star Health is not available in structured form — a significant limitation for a forensic analysis. The cash_flow.json returned empty periods. Indian insurance company annual reports include a Statement of Cash Flows, but it was not extractable from the available data pipeline for this run.
What can be inferred from the balance sheet: Insurance operates on a float model — premiums are collected upfront, invested, and claims paid when they arise. Policyholder funds grew from ₹6,141 Cr (FY2022) to ₹9,960 Cr (FY2025), a 62% increase tracking premium growth. Total investments grew from ₹11,373 Cr to ₹17,898 Cr over the same period (+57%). These trends suggest healthy float accumulation, but do not substitute for the actual cash flow statement.
Investment portfolio quality: Investment income in the P&L has grown steadily alongside the portfolio, with yield stable in the 6.9–8.3% range over five years. The FY2025 shareholder portfolio yield was 7.79% on ₹7,186 Cr in shareholder investments. No unusual asset-quality concerns emerge from these figures.
Key CFO shenanigan tests — status:
The receivable-factoring test (C1) and working-capital-lifeline test (C4) cannot be performed without the cash flow statement. For a health insurer, the conceptually relevant tests are whether premium collection is accelerating or slowing relative to GWP, and whether claim payments are being deferred to inflate period-end cash. The renewal ratio of 99% (management-cited) and the 10% GWP growth consistent with NEP growth (+10.4%) do not suggest aggressive premium acceleration schemes.
Investment income is growing proportionally with the portfolio, and yield is stable — no signs of return-chasing or asset substitution. The equity market exposure, however, creates P&L volatility: Q4 FY2026 saw ₹558 Cr in mark-to-market losses on equity holdings (driven by geopolitical market correction), contributing to a Q4 net loss of ₹55 Cr despite the underlying insurance business turning an underwriting profit.
MTM Equity Exposure: Q4 FY2026 equity MTM loss of ₹558 Cr resulted in a quarterly net loss despite improving underwriting performance. Full-year FY2026 MTM loss was ₹127 Cr. Management introduced a "normalized PAT" concept (8% fixed yield) to remove this volatility from headline reporting — reasonable in concept but adding a third earnings metric to an already crowded disclosure environment.
Metric Hygiene
Management highlights four key metrics in investor communications: GWP growth, combined ratio, normalized PAT, and solvency ratio. Each warrants a forensic test.
1. GWP growth basis mismatch. The statutory annual report adopted 1/n premium recognition from October 2024 per IRDAI mandate. On this basis, FY2025 GWP grew 10% to ₹16,781 Cr. Investor presentations and earnings calls consistently cited 15–16% GWP growth for FY2025 on the "N" (full-premium-at-inception) basis. Management has announced it will fully switch to 1/n basis from FY2027 reporting, meaning investors comparing call numbers to annual report numbers see growth rates that differ by 5–6 percentage points for the same period.
2. Normalized PAT. Introduced in the Q4 FY2026 earnings call, the normalized PAT pegs investment yield at 8% per annum to remove short-term equity MTM volatility. FY2026 normalized PAT was ₹1,222 Cr vs actual IND AS PAT of ₹911 Cr — a 34% premium. The concept has a legitimate purpose (similar to US P&C insurer "operating income" excluding investment gains/losses), but the 8% assumption should be benchmarked against the portfolio's demonstrated historical yield (which has ranged from 6.9% to 8.4% over five years). More importantly, the normalized metric can systematically overstate earnings if equity market returns are persistently below 8% — a scenario that materialized in FY2026.
3. IND AS vs Indian GAAP PAT gap (FY2025). The ₹141 Cr difference (22%) between Indian GAAP (₹646 Cr) and IND AS (₹787 Cr) for the same fiscal year is the largest single metric hygiene concern. The drivers of this gap are not formally reconciled in available disclosures. Likely sources include IFRS 17-style reserve discounting, different investment income recognition, and DAC treatment — but these are educated hypotheses, not confirmed.
4. Solvency ratio. The FY2025 annual report discloses solvency of 2.21× (strong), but the structured data source returns null for this field — meaning investors using financial data services may not see this critical metric. FY2023 loss ratio and combined ratio are also null in the structured data, creating a gap in the COVID-recovery trend series.
The heatmap shows that breeding ground, revenue quality, and cash flow disclosure risk all intensified in FY2025 (loss ratio spike, accounting framework transition) and carried forward into FY2026 (normalized metric introduction). The non-GAAP metric risk is exclusively a FY2026 development. Regulatory actions began in FY2024 with the data breach and escalated in FY2025–26 with the IRDAI SCN.
What to Underwrite Next
The forensic grade is Watch, not Elevated, because no single shenanigan is confirmed — the concerns are about disclosure opacity rather than fabricated numbers. These are the five highest-value items to monitor:
1. FY2026 IND AS Annual Report — PAT reconciliation. The most important forensic data point of the next 12 months. When published (likely September–October 2026), look for the reconciliation of Indian GAAP FY2025 PAT (₹646 Cr) to IND AS FY2025 PAT (₹787 Cr). Line items to examine: insurance contract liability remeasurement under IFRS 17, DAC treatment, investment income recognition, and deferred acquisition cost differences. If the reconciliation is clean and arithmetic, the IND AS gap loses its yellow-flag status. If it reveals reserve releases or reclassifications, the grade moves to Elevated.
2. Normalized PAT — 8% yield stress test. In any quarter where the equity portfolio generates returns meaningfully below 8%, the normalized PAT vs actual PAT gap will widen beyond the FY2026 levels (₹311 Cr delta). Investors should monitor the actual portfolio yield disclosure in quarterly presentations and track whether the 8% normalized assumption is anchored at a realistic level. The forensic trigger: if management raises or lowers the normalized yield rate, that change should be disclosed and explained.
3. IRDAI Show Cause Notice — resolution. The December 2024 SCN for violations during the 2022 inspection has not been resolved in available disclosures. When the IRDAI order is issued (typically within 3–6 months of an SCN), the penalty quantum and the specific violations will be public. A penalty above ₹10 Cr or violations involving product mis-selling would upgrade the regulatory risk to red.
4. Combined ratio under IND AS. The transition to IND AS from April 2026 changes how insurance contract liabilities are measured. Under IFRS 17, claim reserves are measured differently from Indian GAAP, and Contractual Service Margin (CSM) mechanics can shift the timing of profit recognition. If the FY2027 combined ratio on IND AS basis looks materially different from the Indian GAAP equivalent for the same period, that difference needs an explanation.
5. GWP basis switch in FY2027. The company committed to reporting GWP on the 1/n basis from FY2027. The first year's reported growth will appear weaker than N-basis numbers that analysts may be anchoring on. This creates a risk of a perceived "miss" even if underlying business momentum is unchanged. The forensic test: ensure the prior year 1/n restatement is published alongside FY2027 figures so growth is truly comparable.
What would downgrade the forensic grade: If the IND AS reconciliation reveals reserve releases that inflated the IND AS PAT relative to Indian GAAP, or if the IRDAI SCN penalty involves product-level mis-selling that requires re-underwriting of the portfolio, the score would move to Elevated (41–60) range.
What would upgrade the forensic grade: If the FY2026 IND AS annual report publishes a complete PAT reconciliation showing only framework-mechanical differences, the full cash flow statement confirms CFO/NI above 1.0× over three years, and the IRDAI SCN is resolved with a small fine, the grade could improve to Clean (20–25 range).
Position-sizing implication: The accounting risk at Star Health is a valuation-haircut factor, not a thesis breaker. The core business — India's largest standalone health insurer with 31.3% retail market share and 2.21× solvency — has a structural moat that the forensic work does not undermine. The metric complexity demands a higher-than-normal disclosure premium: investors should require a formal IND AS reconciliation before ascribing full value to the IND AS or normalized earnings figures, and should discount the N-basis GWP growth narrative in favor of the statutory 1/n trend when building revenue models.